These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
575 related items for PubMed ID: 24837773
1. Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children. He H, Chen E, Chen H, Wang Z, Li Q, Yan R, Guo J, Zhou Y, Pan J, Xie S. Vaccine; 2014 Jun 30; 32(31):4001-5. PubMed ID: 24837773 [Abstract] [Full Text] [Related]
2. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P. Pediatr Infect Dis J; 2008 Aug 30; 27(8):724-30. PubMed ID: 18600190 [Abstract] [Full Text] [Related]
3. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Marin M, Broder KR, Temte JL, Snider DE, Seward JF, Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep; 2010 May 07; 59(RR-3):1-12. PubMed ID: 20448530 [Abstract] [Full Text] [Related]
4. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age. Goh P, Lim FS, Han HH, Willems P. Infection; 2007 Oct 07; 35(5):326-33. PubMed ID: 17710370 [Abstract] [Full Text] [Related]
5. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age. Vesikari T, Becker T, Gajdos V, Fiquet A, Thomas S, Richard P, Baudin M. Vaccine; 2012 Apr 26; 30(20):3082-9. PubMed ID: 22406278 [Abstract] [Full Text] [Related]
11. Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes. Saffar MJ, Fathpour GR, Parsaei MR, Ajami A, Khalilian AR, Shojaei J, Saffar H. J Trop Pediatr; 2011 Oct 26; 57(5):347-51. PubMed ID: 21078605 [Abstract] [Full Text] [Related]
12. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age. Yadav S, Thukral R, Chakarvarti A. Indian J Med Res; 2003 Nov 26; 118():183-6. PubMed ID: 14723482 [Abstract] [Full Text] [Related]
13. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Vesikari T, Baer M, Willems P. Pediatr Infect Dis J; 2007 Feb 26; 26(2):153-8. PubMed ID: 17259879 [Abstract] [Full Text] [Related]
14. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine. Gillet Y, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P. Vaccine; 2009 Jan 14; 27(3):446-53. PubMed ID: 19007835 [Abstract] [Full Text] [Related]
15. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children. Lee CY, Tang RB, Huang FY, Tang H, Huang LM, Bock HL. Int J Infect Dis; 2002 Sep 14; 6(3):202-9. PubMed ID: 12718836 [Abstract] [Full Text] [Related]